ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

Clinical trial NCT00102700 · COMPLETED

Trial details

NCT number: NCT00102700
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer Adenocarcinoma

Start date: 2005-01-01
Primary completion: 2007-01-01
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.